AI-generated analysis. Always verify with the original filing.
enGene Holdings Inc. announced first quarter 2026 financial results for the three months ended January 31, 2026, reporting $31.2 million in total operating expenses and a net loss of $29.8 million or $0.44 per share, with cash and marketable securities of $312.5 million providing runway into 2H 2028. The company expanded its debt facility to $125 million with Hercules Capital and plans BLA submission for detalimogene in 2H 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 9, 2026, the Company announced its financial results for the three months ended January 31, 2026. A copy
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibits 99.1 Press Release dated March 9, 2026 104 Cover Page Interactive Data File
| Metric | Value | Basis |
|---|---|---|
| Total Operating Expenses | $31.20 | |
| Net Loss Attributable to Common Shareholders | $29.80 | |
| Net Loss per Share | $0.44 |
Debt / Financing